Mark T Iwicki is CHIEF EXECUTIVE OFFICER of Kala Pharmaceuticals, Inc.. Currently has a direct ownership of 263,755 shares of KALA, which is worth approximately $1.63 Million. The most recent transaction as insider was on Jun 26, 2024, when has been sold 15,168 shares (Common Stock) at a price of $4.75 per share, resulting in proceeds of $72,048. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 264K
0% 3M change
4.63% 12M change
Total Value Held $1.63 Million

Mark T Iwicki Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 26 2024
SELL
Open market or private sale
$72,048 $4.75 p/Share
15,168 Reduced 5.44%
263,755 Common Stock
May 31 2024
SELL
Open market or private sale
$45,017 $6.09 p/Share
7,392 Reduced 2.58%
278,923 Common Stock
Jan 04 2024
SELL
Open market or private sale
$30,547 $6.73 p/Share
4,539 Reduced 1.56%
286,315 Common Stock
Jan 04 2024
BUY
Grant, award, or other acquisition
-
14,300 Added 4.69%
290,854 Common Stock
Jun 22 2023
BUY
Grant, award, or other acquisition
-
158,873 Added 36.49%
276,554 Common Stock
May 31 2023
BUY
Grant, award, or other acquisition
-
71,715 Added 37.87%
117,681 Common Stock
Jan 04 2023
SELL
Open market or private sale
$5,650 $28.54 p/Share
198 Reduced 0.43%
45,966 Common Stock
Jan 04 2023
BUY
Grant, award, or other acquisition
-
41,700 Added 47.46%
46,164 Common Stock
Oct 26 2022
SELL
Open market or private sale
$3,658 $6.52 p/Share
561 Reduced 11.16%
4,464 Common Stock
Jun 27 2022
SELL
Open market or private sale
$2,951 $0.37 p/Share
7,975 Reduced 3.08%
251,183 Common Stock
Jan 04 2022
SELL
Open market or private sale
$12,373 $1.3 p/Share
9,518 Reduced 3.54%
259,158 Common Stock
Oct 26 2021
SELL
Open market or private sale
$49,676 $1.8 p/Share
27,598 Reduced 9.32%
268,676 Common Stock
Jun 28 2021
SELL
Open market or private sale
$43,771 $5.77 p/Share
7,586 Reduced 2.5%
296,274 Common Stock
Jan 04 2021
BUY
Grant, award, or other acquisition
-
76,000 Added 20.01%
303,860 Common Stock
Oct 26 2020
BUY
Grant, award, or other acquisition
-
178,300 Added 43.9%
227,860 Common Stock

Also insider at

PULM
Pulmatrix, Inc. Healthcare
MRUS
Merus N.V. Healthcare
AKRO
Akero Therapeutics, Inc. Healthcare
AVTE
Aerovate Therapeutics, Inc. Healthcare
THRD
Third Harmonic Bio, Inc. Healthcare
FIXX
Homology Medicines, Inc. Healthcare
MTI

Mark T Iwicki

CHIEF EXECUTIVE OFFICER
Utretcht, P7

Track Institutional and Insider Activities on KALA

Follow Kala Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALA shares.

Notify only if

Insider Trading

Get notified when an Kala Pharmaceuticals, Inc. insider buys or sells KALA shares.

Notify only if

News

Receive news related to Kala Pharmaceuticals, Inc.

Track Activities on KALA